Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) Debt to Equity (2020 - 2024)

Bicycle Therapeutics (BCYC) has disclosed Debt to Equity for 5 consecutive years, with $0.04 as the latest value for Q2 2024.

  • For Q2 2024, Debt to Equity fell 74.48% year-over-year to $0.04; the TTM value through Jun 2024 reached $0.04, down 74.48%, while the annual FY2023 figure was $0.08, 26.08% down from the prior year.
  • Debt to Equity hit $0.04 in Q2 2024 for Bicycle Therapeutics, down from $0.09 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.21 in Q2 2021 and bottomed at $0.04 in Q2 2024.
  • Average Debt to Equity over 5 years is $0.12, with a median of $0.11 recorded in 2022.
  • Year-over-year, Debt to Equity soared 43.21% in 2023 and then plummeted 74.48% in 2024.
  • Bicycle Therapeutics' Debt to Equity stood at $0.15 in 2020, then tumbled by 43.22% to $0.09 in 2021, then increased by 29.76% to $0.11 in 2022, then decreased by 26.08% to $0.08 in 2023, then plummeted by 57.26% to $0.04 in 2024.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.04, $0.09, and $0.08 for Q2 2024, Q1 2024, and Q4 2023 respectively.